Zoetis Inc. (NYSE:ZTS) Shares Purchased by Advisory Services Network LLC

Advisory Services Network LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 26.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,949 shares of the company’s stock after acquiring an additional 2,905 shares during the period. Advisory Services Network LLC’s holdings in Zoetis were worth $2,633,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC acquired a new stake in Zoetis in the first quarter valued at $26,000. Financial Management Professionals Inc. grew its holdings in Zoetis by 117.4% in the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock valued at $28,000 after purchasing an additional 81 shares during the last quarter. Hanson & Doremus Investment Management grew its holdings in Zoetis by 713.6% in the first quarter. Hanson & Doremus Investment Management now owns 179 shares of the company’s stock valued at $34,000 after purchasing an additional 157 shares during the last quarter. Finally, City State Bank acquired a new stake in Zoetis in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 91.05% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $157.30 on Friday. The business’s 50-day moving average price is $169.59 and its 200 day moving average price is $174.93. Zoetis Inc. has a twelve month low of $154.18 and a twelve month high of $249.27. The company has a market capitalization of $73.64 billion, a PE ratio of 35.67, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14.

Zoetis (NYSE:ZTSGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.02). The business had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 earnings per share. On average, research analysts predict that Zoetis Inc. will post 5.01 earnings per share for the current year.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $175.00, for a total value of $758,450.00. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $175.00, for a total value of $758,450.00. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the completion of the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The disclosure for this sale can be found here. Insiders have sold a total of 16,501 shares of company stock worth $2,949,073 in the last three months. 0.12% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on ZTS shares. The Goldman Sachs Group decreased their price objective on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st. Piper Sandler started coverage on Zoetis in a research note on Monday, July 11th. They set an “overweight” rating and a $205.00 price objective on the stock. StockNews.com raised Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 9th. Stifel Nicolaus decreased their price objective on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, June 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Friday, August 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $224.00.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.